Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome.
Among patients with hypereosinophilia, a myeloproliferative variant is recognized. In many of these patients a diagnosis of eosinophilic leukemia can be made. The molecular mechanism is often a fusion gene, incorporating part of PDGFRA or PDGFRB, encoding anaberrant tyrosine kinase. Prompt diagnosis of such cases is important since specific tyrosine kinase inhibitor therapy is indicated.
Bain
Barbara J
BJ
Department of Haematology, St Mary's Hospital Campus of Imperial College Faculty of Medicine, St Mary's Hospital, Praed Street, London, W2 1NY, UK. b.bain@ic.ac.uk
Fletcher
Sarah H
SH
D002908:Chronic Disease; D016207:Cytokines / Q000378:metabolism; D019337:Hematologic Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000503:physiopathology / Q000628:therapy; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000175:diagnosis / Q000503:physiopathology; D007938:Leukemia / Q000175:diagnosis / Q000235:genetics / Q000503:physiopathology / Q000628:therapy; D009196:Myeloproliferative Disorders / Q000235:genetics / Q000503:physiopathology; D015514:Oncogene Proteins, Fusion / Q000235:genetics / Q000502:physiology; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000235:genetics / Q000502:physiology; D039221:mRNA Cleavage and Polyadenylation Factors / Q000235:genetics / Q000502:physiology
D016207:Cytokines; D015514:Oncogene Proteins, Fusion; D039221:mRNA Cleavage and Polyadenylation Factors; C479819:FIP1L1-PDGFRA fusion protein, human; D020796:Receptor, Platelet-Derived Growth Factor alpha